LEADER 03340nam  22006495  450 
001 9910373905103321
005 20251113184552.0
010   $a981-329-449-3
024 7 $a10.1007/978-981-32-9449-3
035   $a(CKB)4100000010119039
035   $a(DE-He213)978-981-32-9449-3
035   $a(MiAaPQ)EBC6028066
035   $a(PPN)242843360
035   $a(EXLCZ)994100000010119039
100   $a20200123d2019      u|         0
101 0 $aeng
135   $aurnn#008mamaa
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aPathogenicity and Drug Resistance of Human Pathogens $eMechanisms and Novel Approaches /$fedited by Saif Hameed, Zeeshan Fatima
205   $a1st ed. 2019.
210  1$aSingapore :$cSpringer Nature Singapore :$cImprint: Springer,$d2019.
215   $a1 online resource (XXIV, 404 p. 52 illus., 43 illus. in color.)
311 08$a981-329-448-5 
327   $aModule 1_Pathogenicity and Drug resistance in Mycobacterium tuberculosis -- Module 2_ Candida infections and therapeutic strategies -- Module 3_Malarial parasite biology -- Module 4_ Emerging Viral Diseases -- Module 5_Translational Research in Human Microbes.
330   $aThe book comprehensively discusses the mechanisms of pathogenesis and drug resistance; current diagnostics landscape of four key human pathogens; bacterial, fungal, protozoans and viral which are the causes of major infectious diseases. It also assesses the emerging technologies for the detection and quantification of these pathogens. Further, it discusses the novel opportunities to fight against these infectious diseases and to identify pertinent drug targets with novel methodologies. It also reviews the current and future insights into the control, elimination, and eradication of these infectious diseases. Importantly, the book discusses the epidemiological characteristics and various challenges in combating Ebola and Influenza diseases. Finally, the book highlights the growing role of nanotechnology and bioinformatics resources for combating the infectious diseases. In summary, the book provides the mechanistic insight of the pathogenicity, drug-resistance, therapeutic strategies and identification of the novel drug targets of Mycobacterium tuberculosis, Plasmodium, Candida, Hepatitis C and emerging viral infections.
606   $aParasitology
606   $aDiseases
606   $aMedical microbiology
606   $aBioinformatics
606   $aVirology
606   $aParasitology
606   $aDiseases
606   $aMedical Microbiology
606   $aBioinformatics
606   $aVirology
615  0$aParasitology.
615  0$aDiseases.
615  0$aMedical microbiology.
615  0$aBioinformatics.
615  0$aVirology.
615 14$aParasitology.
615 24$aDiseases.
615 24$aMedical Microbiology.
615 24$aBioinformatics.
615 24$aVirology.
676   $a616.9041
702   $aHameed$b Saif$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aFatima$b Zeeshan$4edt$4http://id.loc.gov/vocabulary/relators/edt
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910373905103321
996   $aPathogenicity and Drug Resistance of Human Pathogens$92046980
997   $aUNINA